Overexpression of miRNA 26a and 26b with MMP-9 are valuable diagnostic biomarkers for colorectal cancer patients.

Autor:	Farouk S; Department of Microbial Biotechnology, National Research Centre, Dokki, 12622, Egypt., El-Shenawy R; Department of Microbial Biotechnology, National Research Centre, Dokki, 12622, Egypt., Khairy AM; Department of Endemic Medicine, Faculty of Medicine, Cairo University, Giza, 11562, Egypt., Bader El-Din NG; Department of Microbial Biotechnology, National Research Centre, Dokki, 12622, Egypt.
Jazyk:	angličtina
Zdroj:	Biomarkers in medicine [Biomark Med] 2023 Feb; Vol. 17 (3), pp. 159-169. Date of Electronic Publication: 2023 Apr 25.
DOI:	10.2217/bmm-2022-0861
Abstrakt:	Background: The key role of miRNA expression in incidence and progression of colorectal cancer (CLC) have been developed over the last decade. Materials & methods: A total of 153 subjects were enrolled into two phases: 14 selected miRNAs were first evaluated in 50 subjects, then miR-26a and miR-26b relative expression were further evaluated in 103 subjects and their target protein MMP-9 was measured. Results: miR-26a and -26b showed highly significant overexpression. Both miR-26a and -26b (p < 0.001) had high diagnostic efficacy for CRC. There was a significant increase in serum MMP-9 protein in CRC patients with positive correlation with miR-26a and -26b expression levels (p < 0.001). Conclusion: miRNA 26a and 26b with MMP-9 can be used as diagnostic biomarker for CRC patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu